Navigation Links
JCI early table of contents for Aug. 15, 2013

Biomarkers predict time to ovarian cancer recurrence

Ovarian cancer often remains undetected until it is at an advanced stage. Despite positive responses to initial treatment, many patients are at risk of tumor recurrence. A multitude of genetic markers have been implicated in ovarian cancer prognosis. However, the genetic testing required is not practical or affordable in a clinical setting. In this issue of the Journal of Clinical Investigation, Roel Verchaak and colleagues at the MD Anderson Cancer Center identify protein biomarkers that are predictive for time of ovarian cancer recurrence and develop a PRotein-driven index of OVARian cancer (PROVAR). Using PROVAR, the authors were able to discriminate between patients with high and low risk of cancer recurrence, as well as short-term and long-term survival prognosis. In combination with genetic diagnosis, analysis of protein biomarkers may be useful in predicting outcome and determining a treatment plan for ovarian cancer patients.

TITLE: Predicting Time to Ovarian Carcinoma Recurrence Using Protein Markers

MD Anderson Cancer Center, Houston, TX, USA
Phone: 7135632293; E-mail:

View this article at:

A molecule involved in development of chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease (COPD) is characterized by poor airflow due to the breakdown of lung tissue, mucus accumulation and airway dysfunction. Development of COPD is most commonly associated with smoking tobacco, however, it also occurs after acute respiratory infections such as influenza. It is unclear how prior lung disease leads to COPD. In the current issue of the Journal of Clinical Investigation, Michael Holtzman and colleagues at the Washington University School of Medicine report that expression of an inflammatory molecule, interleukin-33 (IL-33), is increased in the airways of both a mouse model of viral-induced COPD and humans with COPD. Increased IL-33 was associated with an increase in mucus production, and expression of other COPD-implicated genes. The authors found in their mouse model that expression of the gene encoding IL-33 was localized to a population of lungs cells that were induced in the airway after viral infection. These results lay the groundwork for potential therapeutic strategies aimed at preventing COPD after acute lung infection.

TITLE: Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease

AUTHOR CONTACT: Michael Holtzman
Washington University School of Medicine, St. Louis, MO, USA
Phone: 314-362-8970; Fax: 314-362-9002; E-mail:

View this article at:


TITLE: Intestinal Epithelial Vitamin D Receptor Signaling Inhibits Experimental Colitis

The University of Chicago, Chicago, IL, USA
Phone: 773-702-2477; Fax: 773-702-2281; E-mail:

View this article at:

TITLE: Fanconi anemia signaling network regulates the spindle assembly checkpoint

Indiana University, Indianapolis, IN, USA
Phone: 317-278-9290; Fax: 317-274-8679; E-mail:

View this article at:

TITLE: Schnurri-3 regulates ERK downstream of WNT signaling in osteoblasts

Weill Cornell Medical College, New York, NY, USA
Phone: 212-746-2078; Fax: 212-746-9215; E-mail:

View this article at:

TITLE: Differentiation and functional regulation of human fetal NK cells

AUTHOR CONTACT: Jakob Michaelsson
Karolinska Institutet, Stockholm, UNK, SWE
Phone: +46 763142535; E-mail:

View this article at:

TITLE: Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy

Genentech, Inc., South San Francisco, CA, USA
Phone: 650-467-7381; Fax: 650-225-6412; E-mail:

View this article at:


Contact: Corinne Williams
Journal of Clinical Investigation

Related biology technology :

1. Netsmart Clients to Receive Nearly $2 Million in Meaningful Use EHR Incentive Payments
2. Access BridgeGap Ventures to Focus on Early-Stage Therapeutic Opportunities
3. VisionGate Uses $2.6 Million NIH Grant to Achieve Full Automation of Cell-CTâ„¢ 3D Imaging System for Early Diagnosis of Cancer
4. Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook
5. CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms
6. Corporate Venturing and Early-Stage Financing in the Spotlight at BioTrinity
7. Butamax Early Adopters Group surpasses capacity targets with addition of Big River; Membership represents 11 production facilities and nearly 900 million gallons of ethanol capacity
8. Researchers peek at the early evolution of sex chromosomes
9. Discuss Early Results of the DIAN Trial at CBIs 6th Annual Alzheimers Drug Development Summit
10. Early career distinction: Prestigious award recognizes physicists work in electron dynamics
11. JCI early table of contents for Sept. 4, 2012
Post Your Comments:
(Date:10/9/2015)... , ... October 09, 2015 , ... ... However, the current methods of separating those cells from their surroundings for research, ... to the cells. , To address this, Ann Arbor-based startup Akadeum Life ...
(Date:10/8/2015)... WEST PALM BEACH, Fla. , Oct. 8, 2015 ... a leader in synthetic biology, today announced the appointment ... President, Head of Environment Sector, succeeding Nir Nimrodi ... Corporate Development.  Mr. Vaillancourt will direct Intrexon,s endeavors to ... North America , where he held ...
(Date:10/8/2015)... 8, 2015  ATCC, the premier global biological materials ... been selected by The Michael J. Fox Foundation for ... academic, pharmaceutical, and biotechnology organizations committed to speed a ... United States , and more than 5 million ... United States , and more than 5 million ...
(Date:10/8/2015)... , October 8, 2015 ...   --> Goldman Small Cap Research, ... small cap and microcap sectors, announced today that ... on PharmaCyte Biotech, Inc. (OTCQB - PMCB), a ... developing and preparing treatments for cancer and diabetes. ...
Breaking Biology Technology:
(Date:9/30/2015)... 2015  The U.S. Court of Appeals for the ... in favor of Crossmatch ™, affirming the International ... Suprema and its U.S. partner Mentalix violated Section 337 ... that declares it unlawful to engage in "unfair practices" ... Crossmatch,s patents, the 5,900,993 patent and the 7,203,344 patent. ...
(Date:9/29/2015)... News facts: ... energy , Minimized design shrinks PC footprint ... and embedded Fujitsu PalmSecure authentication enable enterprises to realize ... shows that good things come in small packages, with ... enterprise desktop and mobile portfolio. Featuring workplace design that ...
(Date:9/28/2015)... , Sept. 28, 2015 ... today that its expedited traveler service is ... platform transforms travel, bringing a frictionless experience, ... members. "CLEAR offers our travelers ... customer service," said Jim Smith , ...
Breaking Biology News(10 mins):